You are viewing: South Korea Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The South Korea Plasma Fractionation Market was valued at $233.5 Million in 2026 and projected to reach to $310.2 Million by 2031, representing a compound annual growth rate of 5.8%. South Korea's plasma fractionation market is positioned for sustained growth through 2031, driven by an aging population requiring immunological support and hemostatic management.

South Korea Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Plasma Fractionation Market Trends and Insights

  • South Korea's advanced healthcare infrastructure and aging population are driving demand for immunoglobulin therapies, albumin products, and clotting factor concentrates.
  • South Korea's regulatory environment and strong domestic plasma collection capabilities support market expansion through both domestic production and strategic imports. The South Korea plasma fractionation market benefits from rising prevalence of immunodeficiency disorders, bleeding disorders, and chronic inflammatory conditions.
  • South Korea's investment in biopharmaceutical innovation and plasma donor recruitment programs are expected to sustain growth through 2031.
  • South Korea's position within the Asia Pacific region positions it as a key hub for plasma-derived therapeutics, with increasing adoption in hospital and specialty pharmacy settings..

Key Market Statistics

  • CAGR (2026-2031) 5.8% CAGR
  • Market Size, 2026 ~USD 233.5 Million
  • Forecast, 2031 ~USD 310.2 Million
  • Country South Korea

South Korea Plasma Fractionation Market Overview

Market Valuation Growth :

South Korea's plasma fractionation market is valued at USD 233.5 million in 2026 and is projected to reach USD 310.2 million by 2031, demonstrating steady expansion at a 5.8% CAGR.

Aging Population Dynamics :

South Korea's rapidly aging demographic is driving increased demand for immunoglobulin therapies, albumin products, and clotting factor concentrates to address age-related immunological and hemostatic disorders.

Advanced Healthcare Infrastructure :

South Korea's sophisticated healthcare system and high healthcare spending per capita support widespread adoption of plasma-derived therapies and advanced fractionation technologies.

Regulatory Excellence :

South Korea's stringent regulatory environment and alignment with international standards ensure product quality and safety, facilitating market growth and attracting global manufacturers.

South Korea Plasma Fractionation Market Dynamics

  • The country's advanced healthcare infrastructure and high treatment accessibility create favorable conditions for plasma-derived product adoption.
  • Government healthcare policies and reimbursement frameworks continue to support immunoglobulin and albumin therapies.
  • Additionally, South Korea's biopharmaceutical expertise and manufacturing capabilities strengthen domestic production capacity.
  • The market will benefit from increasing awareness of rare bleeding disorders and immunodeficiency conditions, coupled with rising healthcare expenditure among elderly populations..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • South Korea's plasma fractionation market is valued at USD 233.5 million in 2026 and will reach USD 310.2 million by 2031.
      • South Korea is experiencing a 5.8% CAGR, driven by aging demographics and rising immunodeficiency disorder prevalence.
      • South Korea's advanced healthcare infrastructure and regulatory framework support both domestic production and market accessibility.
      • South Korea's strategic position in Asia Pacific makes it a critical market for plasma-derived therapeutic distribution and innovation.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      South Korea Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : Plasma fractionation companies and biopharmaceutical firms need South Korea-specific market data to evaluate market entry feasibility, competitive dynamics, and revenue potential in this advanced healthcare market.
      • Healthcare Investors & PE Firms : Investment professionals require detailed South Korea market analysis to assess portfolio opportunities, valuation benchmarks, and growth trajectories for plasma-derived product companies operating in the region.
      • Medical Device & Diagnostics Companies : Organizations providing plasma collection, testing, and fractionation equipment need South Korea market insights to identify customer bases, regulatory requirements, and technology adoption rates.
      • Healthcare Policy & Government Bodies : South Korean health ministries and regulatory agencies utilize market research to inform reimbursement policies, healthcare planning, and strategic initiatives for plasma-derived therapies.
      • Hospital & Clinical Networks : Healthcare providers and hospital systems in South Korea need market intelligence to optimize procurement strategies, forecast demand for plasma products, and plan therapeutic protocols.

      Reasons to Buy this Report

      • Country-Specific Market Sizing : Obtain precise valuation data for South Korea's plasma fractionation market with verified 2026-2031 forecasts, enabling accurate budget allocation and market entry strategies tailored to this high-income Asian economy.
      • Demographic Insights & Demand Drivers : Understand how South Korea's aging population structure directly impacts demand for immunoglobulin and albumin therapies, with actionable intelligence on patient populations and treatment prevalence.
      • Regulatory & Reimbursement Landscape : Gain detailed analysis of South Korea's regulatory framework, healthcare reimbursement policies, and approval pathways specific to plasma-derived products, reducing market entry risks.
      • Competitive Positioning Analysis : Benchmark your organization against local and international competitors operating in South Korea's plasma fractionation sector with market share and strategic positioning data.
      • Investment & Growth Opportunity Assessment : Identify high-potential segments within South Korea's market, including emerging therapeutic areas and underserved patient populations, to guide R&D and commercialization investments.

      Frequently asked questions

      What is the current size of South Korea's plasma fractionation market?

      South Korea's plasma fractionation market is valued at USD 233.5 million in 2026 and is expected to grow to USD 310.2 million by 2031.

      What is the projected growth rate for South Korea's plasma fractionation market?

      South Korea's plasma fractionation market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2031.

      What factors are driving growth in South Korea's plasma fractionation market?

      South Korea's market growth is driven by an aging population, rising prevalence of immunodeficiency and bleeding disorders, advanced healthcare infrastructure, and strong plasma collection capabilities.

      Which plasma-derived products are most in demand in South Korea?

      South Korea shows strong demand for immunoglobulin therapies, albumin products, and clotting factor concentrates across hospital and specialty pharmacy settings.

      How does South Korea's regulatory environment support the plasma fractionation market?

      South Korea's robust regulatory framework and biopharmaceutical innovation investments facilitate both domestic plasma fractionation production and strategic market access for imported therapies.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status